Criteria for considering studies for this review
|
|
- Ophelia Walker
- 5 years ago
- Views:
Transcription
1 Página 1 de 6 Ovulation induction in women with spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM This protocol should be cited as: Kalantaridou SN, Calis KA, Nelson LM. Ovulation induction in women with spontaneous premature ovarian failure (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update Software. Background Premature ovarian failure (POF) is a condition characterized by amenorrhea, anovulation, sex steroid deficiency, and elevated serum gonadotropin levels in women less than 40 years of age (Rebar 1992; Nelson 1996). It affects 1% of women by the age of 40 (Coulam 1986). Young women can experience POF by several mechanisms, including karyotypic abnormalities, autoimmunity, radiation or chemotherapy, and surgical castration. In most cases the cause of premature ovarian failure is unknown (karyotypically normal spontaneous premature ovarian failure). Women with spontaneous POF have intermittent ovarian follicle function (Rebar 1992; Nelson 1994) and spontaneous pregnancies have occurred after the diagnosis of POF (Polansky 1976; Shangold 1977; Szlachter 1979; Aiman 1985; Ohsawa 1985; Alper 1986; Kreiner 1988). Attempts of ovulation induction in these patients using clomiphene citrate (Shapiro 1977), human menopausal gonadotropins (Johnson 1979), and combination of gonadotropin releasing hormone analogue with purified urinary FSH (Van Kasteren 1995) had no greater ovulation rates than those seen in untreated patients (Rebar 1992). Similarly, controlled studies showed no benefit using gonadotropin-releasing hormone analogue (Nelson 1992) or danazol (Anasti 1994). The aim of this review is to evaluate the evidence from randomized trials that ovulation induction can induce ovulation in women with spontaneous POF. Objectives To investigate whether the use of ovulation induction can induce significantly higher ovulation rates (principal outcome measure) in young women with POF compared with placebo or no treatment. Data on pregnancy rates, live birth rates, and miscarriage rates (secondary outcome measures) will be obtained if available. We will test the hypothesis that: "Ovulation induction (using clomiphene citrate, human menopausal gonadotropins, gonadotropin releasing hormone analogue, a combination of gonadotropin releasing hormone analogue with human menopausal gonadotropins, or other form of ovulation induction) can induce significantly higher ovulation rates in young women with POF compared with placebo or no treatment". Criteria for considering studies for this review Types of studies Studies will be considered for inclusion in this review if they evaluate ovulation rates in patients with karyotypically normal spontaneous POF failure undergoing ovulation induction (using clomiphene citrate, human menopausal gonadotropins, gonadotropin releasing hormone analogue, a combination of gonadotropin releasing hormone analogue with human menopausal gonadotropins, or other form of ovulation induction). Only randomized controlled studies will
2 Página 2 de 6 be considered suitable for inclusion. Types of participants Women with spontaneous POF undergoing ovulation induction in order to induce ovulation. Criteria for karyotypically normal spontaneous premature ovarian failure: 1. Age < 40 years 2. Two FSH levels > 40 miu/ml (at least one month apart) 3. Amenorrhea for at least 4 moths (not due to pregnancy) 4. No evidence of genetic, metabolic, toxic, or iatrogenic cause of the ovarian failure Types of intervention Randomized controlled studies comparing ovulation rates in women with POF will be considered suitable for inclusion in this review. Groups to be compared: women undergoing ovulation induction (using clomiphene citrate, human menopausal gonadotropins, gonadotropin releasing hormone analogue, a combination of gonadotropin releasing hormone analogue with human menopausal gonadotropins, or other form of ovulation induction) compared with control (placebo or no treatment). Types of outcome measures Studies will be considered suitable for inclusion in this review if they evaluate any of the following outcome measures: Primary outcome measure: Ovulation rates [midluteal serum progesterone levels >3 ng/ml (9.5 nmol/l) or in the luteal range for different laboratory asays]. Secondary outcome measures: Pregnancy rates (biochemical evidence of pregnancy, increase in serum beta-hcg levels; pregnancy confirmed by ultrasound); live birth rates; miscarriage rates. Search strategy for identification of studies The literature search will be limited initially to those studies reported in English. Trials reported in a foreign language will be sought over time as resources permit. All publications which describe randomized controlled trials investigating whether the use of ovulation induction can induce significantly higher ovulation rates (or pregnancy rates) in young women with POF compared with placebo or no treatment will be obtained using the search strategy developed by the Menstrual Disorders and Subfertility Group for MEDLINE and hand-searching of specialist journals and examination of review articles (see Review Group details for more information). The reviewers will also search the electronic database EMBASE. In addition, the following terms and variations of these terms will be included: premature ovarian failure premature menopause ovulation induction clomiphene citrate tamoxifen human menopausal gonadotropins gonadotropin releasing hormone analogue Reference lists of included and excluded studies will be inspected. Methods of the review
3 Página 3 de 6 The selection of trials for inclusion in the review will be undertaken by two reviewers (SNK and KAC) employing the search strategy described above. A third reviewer (LMN) will assess any trials where there will be uncertainty regarding eligibility. Any discrepancies will be resolved by discussion. An assessment of the quality of trials and data extraction will be performed independently by the reviewers (SNK, KAC, LMN) using forms designed according to the Cochrane guidelines. Where necessary, additional information on trial methodology or actual original trial data will be sought from the corresponding author of any trials that appear to meet the eligibility criteria. Statistical analysis will be performed in accordance with the guidelines for statistical analysis developed by the Menstrual Disorders and Subfertility Group. Heterogeneity between the results of different studies will be examined by inspecting the scatter in the data points and the overlap in their confidence intervals. Major quality criteria will be given a ranking to enable sensitivity analyses.included trials will be analyzed for the following quality criteria and methodological details: Method of randomization; blinding; number of patients randomized, excluded, or lost to follow up; reporting of the outcome of all the women enrolled and whether the trial was single or multicentered; the presence of power calculation; duration of the study; sources of any funding. Information on the trial participants included age, number of years since the development of ovarian failure, exclusion criteria. Interventions used: types of therapeutic agent used, and dose, duration, and timing of administration of therapeutic agents used. Information on clinical outcomes will be analyzed for ovulation rates (principal outcome measure), pregnancy rates, live birth rates, miscarriage rates (secondary outcome measures). Results from trials using different interventions will be analyzed separately. Sensitivity analysis will be performed according to randomization quality, control group comparison (either placebo or no treatment), equality at baseline, rate of withdrawal and losses to follow-up, intention to treat analysis and length of treatment period. For dichotomous data (for example, proportion of women with POF who ovulate), results for each study will be expressed as a odds ratio with 95% confidence intervals and will be combined for meta-analysis with RevMan software. If the randomized studies controlled studies have different length of therapy, subgroup analysis will be performed. We will combine placebo or no treatment studies. These studies will be analyzed separately as subgroups. This review will include trials that will be located up to April Subsequent eligible trials will be included in an update of this review. Acknowledgements Potential conflict of interest None known References Additional references
4 Página 4 de 6 Aiman 1985 Aiman J, Smentek C. Premature ovarian failure. Obstetrics and Gynecology 1985;66:9-14. Alper 1986 Alper MM, Jolly EE, Garner PR. Pregnancies after premature ovarian failure. Obstetrics and Gynecology 1986;7(Suppl): Anasti 1994 Anasti JN, Kimzey LM, Defensor RA, White B, Nelson LM. A controlled study of danazol for the treatment of karyotypically normal spontaneous premature ovarian failure. Fertility and Sterility 1994;62: Coulam 1986 Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstetrics and Gynecology 1986;67: Johnson 1979 Johnson TR, Peterson EP. Gonadotropin induced pregnancy following "premature ovarian failure". Fertility and Sterility 1979;31: Kreiner 1988 Kreiner D, Droesch K, Navot D, Scott R, Rosenwaks Z. Spontaneous and pharmacologically induced remissions in patients with premature ovarian failure. Obstetrics and Gynecology 1988;73: Nelson 1992 Nelson LM, Kimzey LM, White BJ, Merriam GR. Gonadotropin suppression for the treatment of karyotypically normal spontaneous premature ovarian failure: a controlled trial. Fertility and Sterility 1992;57: Nelson 1994 Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, Shawker TH, Merino MJ. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. Journal of Clinical Endocrinology and Metabolism 1994;79: Nelson 1996 Nelson LM, Anasti JN, Flack MR. Premature ovarian failure. In: Adashi EY, Rock JA, Rozenwaks Z, editor(s). Reproductive endocrinology, surgery and technology 1st Edition. Philadelphia: Lippincott-Raven, 1996: Ohsawa 1985 Ohsawa M, Wu MC, Masahashi T, Asai M, Narita O. Cyclic therapy resulted in pregnancy in premature ovarian failure. Obstetrics and Gynecology 1985;66(3 Suppl):64-67.
5 Página 5 de 6 Polansky 1976 Polansky S, DePapp EW. Pregnancy associated with hypergonadotropic hypogonadism. Obstetrics and Gynecology 1976;47(Suppl): Rebar 1992 Rebar RW, Cedars MI. Hypergonadotropic forms of amenorrhea in young women. Endocrinology and Metabolism Clinics of North America 1992;21: Shangold 1977 Shangold MM, Turksoy RN, Bashford RA, Hammond CB. Pregnancy following the "insensitive ovary syndrome". Fertility and Sterility 1977;28: Shapiro 1977 Shapiro AG, Rubin A. Spontaneous pregnancy in association with hypergonadotropic ovarian failure. Fertility and Sterility 1977;28: Szlachter 1979 Szlachter BN, Nachtigall LE, Epstein J, Young BK, Weiss G. Premature menopause: a reversible entity?. Obstetrics and Gynecology 1979;54: Van Kasteren 1995 Van Kasteren YM, Hoek A, Schoemaker J. Ovulation induction in premature ovarian failure: A placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation. Fertility and Sterility 1995;64: Cover sheet Ovulation induction in women with spontaneous premature ovarian failure Reviewer(s) Contribution of Reviewer(s) Kalantaridou SN, Calis KA, Nelson LM Sophia N. Kalantaridou: Took the lead in writing the protocol, developed objectives, selection criteria, methods and background. Karim A. Calis: Contributed to background section. Developed and performed search strategy. Lawrence M. Nelson: Conceptualised and edited the protocol. Issue protocol first published Date of last minor amendment 2001 issue 3 Information not supplied by reviewer
6 Página 6 de 6 Date of last substantive amendment Most recent changes Review expected to be published in: Contact address Cochrane Library number Editorial group Editorial group code 31 May 2001 Information not supplied by reviewer Issue 3, 2003 Ms Sophia Kalantaridou Kosti Palama 3 Ioannini GREECE 5042 Telephone: Facsimile: Kalantas@exchange.nih.gov CD Cochrane Menstrual Disorders and Subfertility Group MENSTR Additional tables Additional tables are not available for this protocol Print Close
Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol]
Página 1 de 7 Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM. This protocol should be cited
More informationIOF POI. hypergonadotropic hypogonadism primary ovarian insufficiency POI /premature ovarian failure POF. Van Kasteren. Coulam POI FSH E.
hypergonadotropic hypogonadism primary ovarian insufficiency POI /premature ovarian failure POF Coulam POI Turner Fragile X premutation FSHR NOBOX FOXL etc POI FSH miu/ml AMH AMH AMH FSH / Knauff POI IOF
More informationPremature Ovarian Failure: Is there a role for steroids? A randomized, double-blind, placebo-controlled trial.
Premature Ovarian Failure: Is there a role for steroids? A randomized, double-blind, placebo-controlled trial. Rebecca Fenichel A. Study Purpose and Rationale Premature ovarian failure is a condition causing
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationHossam ElDeen ElShenoufy M.Sc. Assistant lecturer Obstetrics & Gynecology Cairo University
Training Course in Sexual and Reproductive Health Research Geneva, 2 March 2009 IAMANEH Scholarship Hossam ElDeen ElShenoufy M.Sc. Assistant lecturer Obstetrics & Gynecology Cairo University Presentation
More informationSuperovulation with human menopausal gonadotropins is associated with endometrial gland-stroma dyssynchrony*
aes FERTILITY AND STERILITY Vol. 61, No.4, April 1994 Copyright ee) 1994 The American Fertility Society Printed on acid-free paper in U. S. A. r I Superovulation with human menopausal gonadotropins is
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationOvulation induction in premature ovarian failure: a placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation
FERTILITY AND STERILITY Copyright 1995 American Society for Reproductive Medicine Vol. 64, No.2, August 1995 Printed on acid-free paper in U. S. A. Ovulation induction in premature ovarian failure: a placebo-controlled
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness Gerli S, Casini M L, Unfer V, Costabile L, Bini V,
More informationNIH Public Access Author Manuscript Fertil Steril. Author manuscript; available in PMC 2011 October 1.
NIH Public Access Author Manuscript Published in final edited form as: Fertil Steril. 2010 October ; 94(5): 1769 1774. doi:10.1016/j.fertnstert.2009.10.023. A prospective evaluation of antral follicle
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More informationElena H. Yanushpolsky, M.D., a Shelley Hurwitz, Ph.D., b Eugene Tikh, B.S., c and Catherine Racowsky, Ph.D. a
FERTILITY AND STERILITY VOL. 80, NO. 1, JULY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Predictive usefulness of cycle
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationSTIMULATION AND OVULATION TRIGGERING
STIMULATION AND OVULATION TRIGGERING Professor IOANNIS E. MESSINIS MD, PhD (Aberdeen, UK), FRCOG (UK) Department of Obs/Gynae University of Thessaly Larissa, GREECE DISCLOSURE Nothing to disclose Learning
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationReproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives
Reproductive Testing: Less is More G. Wright Bates, Jr., M.D. Professor and Director Reproductive Endocrinology and Infertility Objectives 1. Review definition of infertility and impact of age 2. Stress
More informationOpen Access. Mohamed K. Moustafa 1,2, Ahmed R. Abdelwahed 2, Ibrhium Abosekena 2, Shokry Abdelazim 2, Ahmed M. Abou-Setta 3 and Hesham G.
The Open Women s Health Journal, 2009, 3, 11-15 11 Open Access IVF Outcomes with Either Highly Purified FSH vs. Recombinant FSH in Down-Regulated Normogonadotrophic Women: A Prospective Comparative Study
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationProf. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany
Induction of fertility in hypogonadal men Prof. Dr. Michael Zitzmann Internal Medicine Endocrinology, Diabetology, Andrology University of Muenster, Germany Induction of fertility in hypogonadal men Prof.
More informationLUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY*
FERTILITY AND STERILITY Copyright c 1978 The American Fertility Society Vol. 29, No.3, March 1978 Printed in U.S.A. LUTEINIZED UNRUPTURED FOLLICLE SYNDROME: A SUBTLE CAUSE OF INFERTILITY* JAROSLA V MARIK,
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Injectable Fertility Medications: Bravelle, Cetrotide, Follistim AQ, Ganirelix, Gonal-F, human chorionic gonadotropin, leuprolide, Menopur, Novarel, Ovidrel, Pregnyl,
More informationwww.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 8/15/18 Pharmacy- Formulary 1 x Next Review: 6/18 Pharmacy- Formulary 2 x Date of Origin: 7/00 Injectable Fertility Medications: Bravelle,
More information- Meta. : (rfsh); (ufsh); (IVF); : R711.6 : A : X(2015) : hmg( FSH LH) [ufsh, (ufsh-p) (ufsh-hp)] (rfsh) [1] 80, rfsh, 90, :
35 2 Vol.35 No.2 2015 2 Feb. 2015 Reproduction & Contraception doi: 10.7669/j.issn.0253-357X.2015.02.0099 E-mail: randc_journal@163.com (FSH) - Meta FSH ( 400010) : (IVF) (ICSI) (rfsh) (ufsh) (COS) : PubMed
More information10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.
The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence
More informationCommon protocols in intra-uterine insemination cycles
Common protocols in intra-uterine insemination cycles Doç. Dr. Candan İltemir Duvan Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum AD Ovulation induction with intra-uterine insemination
More informationHCG (human chorionic gonadotropin); Novarel Pregnyl (chorionic gonadotropin); Ovidrel (choriogonadotropin alfa)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.09 Subject: HCG Page: 1 of 5 Last Review Date: June 19, 2015 HCG Powder, Novarel, Pregnyl, Ovidrel
More informationEgg donation in an in vitro fertilization program: an alternative approach to cycle synchronization and timing of embryo transfer
FERTILITY AND STERILITY Copyright tl 1989 The American Fertility Society Printed on acid-free paper in U. S.A. Egg donation in an in vitro fertilization program: an alternative approach to cycle synchronization
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal myomectomy in leiomyoma management, 77 Abnormal uterine bleeding (AUB) described, 103 105 normal menstrual bleeding vs., 104
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More informationCurrent Evidence On Infertility Treatment
Current Evidence On Infertility Treatment Mahmoud A.M. Abdel-Aleem Regina Kulier WHO/GFMER 2003 Problem of Infertility It is a state in which a couple, desirous of a child, cannot conceive after 12 months
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationPoor & Hyper responders: what is the best approach?
Poor & Hyper responders: what is the best approach? A. La Marca ObGyn Dept University of Modena and Reggio Emilia Italy Center for Reproductive Medicine University Hospital of Modena Italy Criteria used
More informationLink between effectiveness and cost data The costing was undertaken prospectively on the same patient sample that provided the effectiveness data.
Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-fsh vs. HPuFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis Revelli A, Poso F, Gennarelli
More informationManagement of Patients With Premature Ovarian Insufficiency
Management of Patients With Premature Ovarian Insufficiency Prof. Dr. H. Cavidan Gülerman Sağlık Bilimleri Üniversitesi Ankara Dr. Zekai Tahir Burak SUAM XII. Türk Alman Jinekoloji Kongresi 28 Nisan 2018
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationART Drugs. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: September 15, 2017 ART Drugs Description Bravelle
More informationResearch and Health Policy Studies, Tufts-New England Medical Center, Boston, Massachusetts
Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis Ioannis P. Kosmas, M.D., a Athina
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationme LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS
FERTILITY AND STERILITY Copyright c 980 The American Fertility Society Vol. 33,, JanuaEY 980 Printed in U.S.A. me LUTEINIZED UNRUPTURED FOLLICLE SYNDROME AND ENDOMETRIOSIS W. PAULDMOWSKI, M.D.,.PH.D.*
More information10.7 The Reproductive Hormones
10.7 The Reproductive Hormones December 10, 2013. Website survey?? QUESTION: Who is more complicated: men or women? The Female Reproductive System ovaries: produce gametes (eggs) produce estrogen (steroid
More informationSynchronised approach for intrauterine insemination in subfertile couples Cantineau, Astrid E. P.; Janssen, Mirjam J.; Cohlen, Ben J.
University of Groningen Synchronised approach for intrauterine insemination in subfertile couples Cantineau, Astrid E. P.; Janssen, Mirjam J.; Cohlen, Ben J. Published in: Cochrane Database of Systematic
More informationHormone Balance - Female Report SAMPLE. result graph based on Luteal Phase. result graph based on Luteal Phase
Patient Name: Patient DOB: Gender: Physician: Test Hormone Balance - Female Report SAMPLE Grote, Mary Jane Batch Number: B6437 2/16/1954 Accession Number: N52281 F Date Received: 2/3/2015 Any Lab Test
More informationThe importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in women with anovulatory infertility
FERTILITY AND STERILITY Copyright 0 1988 The American Fertility Society Printed in U.S.A. The importance of human chorionic gonadotropin support of the corpus luteum during human gonadotropin therapy in
More informationIntercycle variability of day 3 follicle-stimulating hormone levels and its effect on stimulation quality in in vitro fertilization*
FERTILITY AND STERILITY Copyright C> 1990 The American Fertility Society Printed on acid-free paper in U.S.A. Inter variability of day 3 follicle-stimulating hormone levels and its effect on stimulation
More informationA Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist
1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang
More informationN. Shirazian, MD. Endocrinologist
N. Shirazian, MD Internist, Endocrinologist Inside the ovary Day 15-28: empty pyfollicle turns into corpus luteum (yellow body) Immature eggs Day 1-13: 13: egg developing inside the growing follicle Day
More informationInvestigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle?
Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle? Introduction: The menstrual cycle (changes within the uterus) is an approximately 28-day cycle that
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationVaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer
Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization embryo transfer Mohamed F. Mitwally, M.D., H.C.L.D., a Michael P. Diamond,
More informationA multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of
A multi-centre, multinational, cross-sectional, incident case control study on Factors associated with the development of Endometrioma and deep infiltrating endometriosis Professor C. Chapron and the Group
More informationFertility Apps Do not Help You Get pregnant
Fertility Apps Do not Help You Get pregnant Fertility Apps Do not Help You Get pregnant Beyond Regular Intercourse Many women use fertility apps to track their menstrual cycle and time intercourse. Tracking
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More informationInfertility: A Generalist s Perspective
Infertility: A Generalist s Perspective Learning Objectives Fertility and Lifestyle: Patient education Describe the basic infertility workup Basic treatment strategies unexplained Heather Huddleston, MD
More informationCauses of Infertility and Treatment Options
Causes of Infertility and Treatment Options Dr Mrs.Kiran D. Sekhar Former vice President-FOGSI Former Chairperson- Genetics and Foetal medicine-fogsi Founder and Medical Director-Kiran Infertility centre
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationT A B L E O F C O N T E N T S
Short-term psychodynamic psychotherapies for anxiety, depression and somatoform disorders (Unknown) Abbass AA, Hancock JT, Henderson J, Kisely S This is a reprint of a Cochrane unknown, prepared and maintained
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationCharacterization of idiopathic premature ovarian failure
FERTILITY AND STERILITY Copyright 1996 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Characterization of idiopathic premature ovarian failure Gerard S. Conway, M.D.
More informationReproductive hormones and epilepsy
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 7 Treatment of women with epilepsy - Level 1-2 Reproductive hormones and epilepsy Gerhard
More informationBACKGROUNDER. Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive
BACKGROUNDER Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive Studies find that increased chances of ovulation, menstrual
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationLetrozole versus Clomiphene Citrate in Patients with Anovulatory Infertility
South Asian Letrozole Federation versus of Clomiphene Obstetrics Citrate and Gynecology, in Patients with January-April Anovulatory Infertility 2009;1(1):19-23 ORIGINAL STUDIES Letrozole versus Clomiphene
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationLow Dose hmg As a First choice for Ovarian Stimulation in IUI cycles
Low Dose hmg As a First choice for Ovarian Stimulation in IUI cycles aslan, M.D Department of Obstetrics & Gynecology, Cairo University Abstract Objective: to compare pregnancy rates following low dose
More informationObjectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility
STILL A PLACE FOR PILLS DON T IVF EVERYTHING Jeff Roberts M.D. Co-Director, Pacific Centre for Reproductive Medicine Objectives 1 2 3 4 5 Clomiphene citrate and Letrozole Infertility Case Studies Unexplained
More informationEvaluation of Dehydroepiandrosterone Supplementation on Diminished Ovarian Reserve: A Randomized, Double-Blinded, Placebo-Controlled Study
The Journal of Obstetrics and Gynecology of India (March April 2017) 67(2):137 142 DOI 10.1007/s13224-016-0941-8 ORIGINAL ARTICLE Evaluation of Dehydroepiandrosterone Supplementation on Diminished Ovarian
More informationOvarian response in three consecutive in vitro fertilization cycles
FERTILITY AND STERILITY VOL. 77, NO. 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Ovarian response in
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationLUTEINIZING HORMONE-RELEASING HORMONE FOR INDUCTION OF FOLLICULAR MATURATION AND OVULATION IN WOMEN WITH INFERTILITY AND AMENORRHEA*
FERTILITY AND STERILITY Copyright < 1976 The American Fertility Society Vol. 27, No.6, June 1976 Printed in V.SA. LUTEINIZING HORMONE-RELEASING HORMONE FOR INDUCTION OF FOLLICULAR MATURATION AND OVULATION
More informationDr. Matteo Lambertini
CONGRESSO NAZIONALE AIOM GIOVANI SESSIONE: PREMIAZIONE MIGLIORI TRE LAVORI GIOVANI SOPPRESSIONE OVARICA CON LHRH ANALOGHI DURANTE CHEMIOTERAPIA PER LA PRESERVAZIONE DELLA FUNZIONE OVARICA E DELLA FERTILITÀ
More informationCommissioning Brief - Background Information. Letrozole for improving fertility in women with polycystic ovary syndrome
Commissioning Brief - Background Information Letrozole for improving fertility in women with polycystic ovary syndrome HTA no 17/116 This background document provides further information to support applicants
More informationRisk factors for spontaneous abortion in menotropintreated
FERTILITY AND STERILITY Copyright ~ 1987 The American Fertility Society Vol. 48, No. 4, October 1987 Printed in U.S.A. Risk factors for spontaneous abortion in menotropintreated women Michael Bohrer, M.D.*
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationInfertility DR. RAHUL BEVARA
Infertility DR. RAHUL BEVARA Definitions Infertility is defined as the inability to conceive after one year of unprotected coitus. Affects 10-15% of couples Primary Infertility, that is inability to conceive
More informationEvidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors.
Evidence tables from the systematic literature search for premature ovarian insufficiency surveillance in female CAYA cancer survivors. Who needs surveillance? Chiarelli et al. Early menopause and Infertility
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationEndocrine profiles in tamoxifen-induced conception cycles
FERTILITY AND STERILITY Copyright" 1984 The American Fertility Society Printed in U.S A. Endocrine profiles in tamoxifen-induced conception cycles Choshin Tajima, M.D. Department of Obstetrics and Gynecology,
More informationIVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)
34 11 Vol.34 No.11 2014 11 Nov. 2014 Reproduction & Contraception doi: 10.7669/j.issn.0253-3X.2014.11.0892 E-mail: randc_journal@163.com IVF ( 710003) : (H-hMG) - (IVF- ET) : GnRH H-hMG (H-hMG ) (rfsh
More informationClomid success for premature ovarian failure
P ford residence southampton, ny Clomid success for premature ovarian failure The clomid challenge test is used to identify women with decreased ovarian reserve and a poor potential for producing a viable
More informationPolycystic Ovary Syndrome
What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular
More informationArticle Effect of cetrorelix dose on premature LH surge during ovarian stimulation
RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation
More informationTime / days. Explain how the release of FSH is controlled by negative feedback.
1. The graph shows the changes in concentration of the hormones responsible for controlling the menstrual cycle. A Hormone concentration Oestrogen B C 0 14 28 Time / days WD Phillips and TJ Chilton A Level
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationA cost comparison of infertility treatment for clomiphene resistant polycystic ovary syndrome Fridstrom M, Sjoblom P, Granberg M, Hillensjo T
A cost comparison of infertility treatment for clomiphene resistant polycystic ovary syndrome Fridstrom M, Sjoblom P, Granberg M, Hillensjo T Record Status This is a critical abstract of an economic evaluation
More informationBleeding and spontaneous abortion after therapy for infertility
FERTILITY AND STERILITY VOL. 74, NO. 3, SEPTEMBER 2000 Copyright 2000 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Bleeding and spontaneous
More informationAssisted Reproduction. Rajeevi Madankumar, 1,2 James Tsang, 1 Martin L. Lesser, 1 Daniel Kenigsberg, 1 and Steven Brenner 1 INTRODUCTION
( C 2005) DOI: 10.1007/s10815-005-4912-8 Assisted Reproduction Clomiphene citrate induced ovulation and intrauterine insemination: effect of timing of human chorionic gonadotropin injection in relation
More information